When was Basilea founded?

Basilea was founded in 1999 and raised its 1st funding round 2 years after it was founded.

Where is Basilea located?

Basilea is headquartered in Basel, Switzerland.

How many employees does Basilea have?

As of Aug 31, 2026, the latest employee count at Basilea is 259.

Is Basilea a funded company?

Basilea is a funded company, having raised an undisclosed amount across 9 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on 2001.

When was the latest funding round of Basilea?

Basilea's latest funding was a $***** Grant (prize money) round on May 28, 2026, with participation from 1 investor.

Where does Basilea rank among its competitors?

Basilea ranks 4th amongst 145 active competitors, of which 42 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Basilea?

Basilea's top competitors include Insmed, Evofem and Imvax. Among them, Basilea secured the most recent funding round in May, 2026.

Basilea - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases. Its product portfolio includes ceftobiprole for pneumonia, isavuconazole for fungal infections, and 3 other pipeline products under development. It also has a leading candidate BAL 101553 for recurrent or progressive glioblastoma.

Website: www.basilea.com
Email ID: *****@basilea.com

Key Metrics

Founded Year

1999

Location

Basel, Switzerland

Stage

Public

Latest Funding Round

Grant (prize money), May 28, 2026, $*****

Investors

Athyrium Capital Management & 3 more

Ranked

4^th among 145 active competitors

Employee Count

259 as on Aug 31, 2026

Similar Companies

Insmed & 178 more

Exit Details

Public

View Basilea's full profile

Basilea is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Basilea Pharmaceutica Ltd CIN: 101.175.068 , Switzerland, Active	Jan 01, 1999	-	-	-
BASILEA PHARMACEUTICALS A/S CIN: 30723732 , Denmark, Deadpooled	Jul 09, 2007	-	-

Basilea got listed on Mar 25, 2004.

Click here to take a look at Basilea's IPO in detail

Basilea has raised funding over 9 rounds. Its first funding round was on 2001. Its latest funding round was a Grant (prize money) round on May 28, 2026 for $*****. 1 investor participated in its latest round. Basilea has 4 institutional investors.

Here is the list of recent funding rounds of Basilea:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 28, 2026	2230682	Grant (prize money)	1592675	2886466	5576133	8960477
Feb 25, 2026	9294652	Grant (prize money)	3213229	4029697	3353303	Medical Countermeasures
Dec 23, 2024	1626476	Grant (prize money)	1998363	9183375	7395798	CARB-X

Access funding benchmarks and valuations. Sign up today!

View details of Basilea's funding rounds and investors

Basilea's employee count trend

Basilea has 259 employees as of Aug 26. Here is Basilea's employee count trend over the years:

Uncover Basilea's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Basilea include Insmed, Evofem and Imvax. Here is the list of Top 10 competitors of Basilea, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
2nd	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	65/100
3rd	Imvax 2015, Philadelphia (United States), Series C	Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity	$204M	Hp Wild Holding, Magnetar & 4 others	62/100
4th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
5th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	Boehringer Ingelheim Venture Fund, REPAIR Impact Fund ... & 32 others	58/100
6th	Eubiologics 2012, Seoul (South Korea), Public	Company providing customized services for development and manufacturing biologics from both mammalian cell and microbial-based systems.	$7.5M	IMM Investment, Global Health Investment Fund ... & 8 others	56/100
7th	SNIPR Biome 2011, Copenhagen (Denmark), Series B	Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely	$139M	Lundbeck Foundation, Life Sciences Partners ... & 7 others	55/100
8th	Minervax 2010, Hellerup (Denmark), Series C	Developer of vaccines against life-threatening infections in newborns	$197M	Orbimed, EQT & 14 others	54/100
9th	SOM Biotech 2009, Barcelona (Spain), Series B	Developer of platform for screening compounds to treat rare diseases	$28.5M	European Investment Bank, Prevail Partners ... & 3 others	53/100
10th	Prokarium 2012, London (United Kingdom), Series C	Developer of bacterial immunotherapy treatments for various types of cancer	$70M	Korea Investment Holdings, Riyadh Valley Company ... & 9 others	52/100